Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis

Xu,Fei; Dong,Yonghui; Huang,Xin; Chen,Peng; Guo,Fengjing; Chen,Anmin; Huang,Shilong

doi:10.3892/mmr.2016.5515

Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis

Authors:
- Fei Xu
- Yonghui Dong
- Xin Huang
- Peng Chen
- Fengjing Guo
- Anmin Chen
- Shilong Huang
View Affiliations

Affiliations: Department of Orthopedics, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: July 13, 2016 https://doi.org/10.3892/mmr.2016.5515
Pages: 2289-2296

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thiazolidinediones are traditional anti‑diabetic therapeutic agents that have been associated with bone loss and increased fracture risk. However, the underlying mechanisms of this side effect require further elucidation. The present study aimed to investigate the effect of pioglitazone (PIO), a thiazolidinedione, on osteoblastogenesis, osteoclastogenesis and the osteoprotegerin (OPG) / receptor activator of nuclear factor‑κB ligand (RANKL) / RANK system. The MC3T3‑E1 murine pre‑osteoblastic cell line was treated with PIO and processed for reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) analysis of OPG, RANKL, peroxisome proliferator‑activated receptor γ (PPARγ), Runt‑related transcription factor 2 (RUNX2), alkaline phosphatase (ALP) and osteocalcin (OCN), and western blotting analysis of OPG and RANKL. The culture medium was collected for ELISA analysis of OPG and RANKL. Murine bone marrow monocytes (BMMCs) were treated with PIO in the presence of RANKL and macrophage‑colony stimulating factor and subjected to tartrate‑resistant acid phosphatase (TRAP) staining and activity measurement, and RT‑qPCR analysis of cathepsin K, TRAP and RANK. Co‑culture of MC3T3‑E1 and BMMCs was performed in the presence of PIO, and TRAP staining was also conducted. PIO inhibited the osteoblastic differentiation of MC3T3‑E1 cells, and promoted the osteoclastic differentiation of BMMCs with or without co‑culturing with MC3T3‑E1 cells. ELISA analysis indicated increased RANKL and decreased OPG expression levels in the medium of MC3T3‑E1 cells treated with PIO. PIO upregulated expression of RANKL and PPARγ and downregulated expression of OPG, RUNX2, ALP and OCN in MC3T3‑E1 cells, while expression levels of RANK in BMMCs remained unchanged. These results suggest that PIO suppresses osteoblastogenesis and enhances osteoclastogenesis. In addition, PIO may also promote osteoclastogenesis by affecting the OPG‑RANKL‑RANK system.

View Figures

View References

1	Derosa G: Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: Comparison with other oral antihyperglycaemic agents. Drugs. 70:1945–1961. 2010. View Article : Google Scholar : PubMed/NCBI
2	McDonough AK, Rosenthal RS, Cao X and Saag KG: The effect of thiazolidinediones on BMD and osteoporosis. Nat Clin Pract Endocrinol Metab. 4:507–513. 2008. View Article : Google Scholar : PubMed/NCBI
3	Montagnani A and Gonnelli S: Antidiabetic therapy effects on bone metabolism and fracture risk. Diabetes Obes Metab. 15:784–791. 2013. View Article : Google Scholar : PubMed/NCBI
4	Raggatt LJ and Partridge NC: Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 285:25103–25108. 2010. View Article : Google Scholar : PubMed/NCBI
5	Lazner F, Gowen M, Pavasovic D and Kola I: Osteopetrosis and osteoporosis: Two sides of the same coin. Hum Mol Genet. 8:1839–1846. 1999. View Article : Google Scholar : PubMed/NCBI
6	Khosla S: Minireview: The OPG/RANKL/RANK system. Endocrinology. 142:5050–5055. 2001. View Article : Google Scholar : PubMed/NCBI
7	Eriksen EF: Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. 11:219–227. 2010. View Article : Google Scholar : PubMed/NCBI
8	Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM and Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 270:12953–12956. 1995. View Article : Google Scholar : PubMed/NCBI
9	Tontonoz P, Hu E and Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 79:1147–1156. 1994. View Article : Google Scholar : PubMed/NCBI
10	MacDougald OA and Lane MD: Transcriptional regulation of gene expression during adipocyte differentiation. Annu Rev Biochem. 64:345–373. 1995. View Article : Google Scholar : PubMed/NCBI
11	Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM and Morris DC: Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol. 50:1087–1094. 1996.PubMed/NCBI
12	Mabilleau G, Chappard D and Baslé MF: Cellular and molecular effects of thiazolidinediones on bone cells: A review. Int J Biochem Mol Biol. 2:240–246. 2011.PubMed/NCBI
13	Wang L, Li L, Gao H and Li Y: Effect of pioglitazone on transdifferentiation of preosteoblasts from rat bone mesenchymal stem cells into adipocytes. J Huazhong Univ Sci Technolog Med Sci. 32:530–533. 2012. View Article : Google Scholar : PubMed/NCBI
14	Liu L, Aronson J and Lecka-Czernik B: Rosiglitazone disrupts endosteal bone formation during distraction osteogenesis by local adipocytic infiltration. Bone. 52:247–258. 2013. View Article : Google Scholar
15	Cho ES, Kim MK, Son YO, Lee KS, Park SM and Lee JC: The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption. Mol Cells. 33:173–181. 2012. View Article : Google Scholar : PubMed/NCBI
16	Viccica G, Francucci CM and Marcocci C: The role of PPARγ for the osteoblastic differentiation. J Endocrinol Invest. 33(Suppl 7): S9–S12. 2010.
17	Yamashita A, Takada T, Nemoto K, Yamamoto G and Torii R: Transient suppression of PPARgamma directed ES cells into an osteoblastic lineage. FEBS Lett. 580:4121–4125. 2006. View Article : Google Scholar : PubMed/NCBI
18	Jeon MJ, Kim JA, Kwon SH, Kim SW, Park KS, Park SW, Kim SY and Shin CS: Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem. 278:23270–23277. 2003. View Article : Google Scholar : PubMed/NCBI
19	Bruedigam C, Eijken M, Koedam M, van de Peppel J, Drabek K, Chiba H and van Leeuwen JP: A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone. Stem Cells. 28:916–927. 2010.PubMed/NCBI
20	Teitelbaum SL and Ross FP: Genetic regulation of osteoclast development and function. Nat Rev Genet. 4:638–649. 2003. View Article : Google Scholar : PubMed/NCBI
21	Chan BY, Gartland A, Wilson PJ, Buckley KA, Dillon JP, Fraser WD and Gallagher JA: PPAR agonists modulate human osteoclast formation and activity in vitro. Bone. 40:149–159. 2007. View Article : Google Scholar
22	Wan Y, Chong LW and Evans RM: PPAR-gamma regulates osteoclastogenesis in mice. Nat Med. 13:1496–1503. 2007. View Article : Google Scholar : PubMed/NCBI
23	Wu H, Li L, Ma Y, Chen Y, Zhao J, Lu Y and Shen P: Regulation of selective PPARγ modulators in the differentiation of osteoclasts. J Cell Biochem. 114:1969–1977. 2013. View Article : Google Scholar : PubMed/NCBI
24	Wei W, Wang X, Yang M, Smith LC, Dechow PC, Sonoda J, Evans RM and Wan Y: PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab. 11:503–516. 2010. View Article : Google Scholar : PubMed/NCBI
25	Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ and Riggs BL: The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 15:2–12. 2000. View Article : Google Scholar : PubMed/NCBI
26	Muruganandan S, Roman AA and Sinal CJ: Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: Cross talk with the osteoblastogenic program. Cell Mol Life Sci. 66:236–253. 2009. View Article : Google Scholar
27	Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ and Lecka-Czernik B: Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology. 148:2669–2680. 2007. View Article : Google Scholar : PubMed/NCBI
28	Park JS, Cho MH, Nam JS, Yoo JS, Ahn CW, Cha BS, Kim KR and Lee HC: Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. Eur J Endocrinol. 164:69–74. 2011. View Article : Google Scholar
29	Sultan A, Avignon A, Galtier F, Piot C, Mariano-Goulart D, Dupuy AM and Cristol JP: Osteoprotegerin, thiazolidinediones treatment and silent myocardial ischemia in type 2 diabetic patients. Diabetes Care. 31:593–595. 2008. View Article : Google Scholar
30	Krause U, Harris S, Green A, Ylostalo J, Zeitouni S, Lee N and Gregory CA: Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proc Natl Acad Sci USA. 107:4147–4152. 2010. View Article : Google Scholar : PubMed/NCBI